To further explore the efficacy of immunotherapy in patients with ALK rearranged NSCLC, data from clinical trials combining immune checkpoints with treatment strategies such as ALK TKIs, chemotherapy and anti angiogenic agents are summarized. This evidence concerns the gene ALK and non-small cell lung carcinoma.